Navigation Links
GM, Coskata partnership builds on Oklahoma State University biofuels research
Date:1/16/2008

STILLWATER, Okla. The Oklahoma State University Biofuels Teams ability to think small microscopic, actually stands to provide great dividends for consumers, a renewable energy company and one of the nations foremost automakers.

Biology based renewable energy company Coskata Inc. and automotive giant General Motors announced their cooperative plans to reduce fossil fuel consumption this past weekend, thanks in part to Coskatas next generation ethanol process based on research and technology developed by the OSU Biofuels Team and licensed exclusively to Coskata.

Coskatas unique three-step conversion process addresses many of the constraints lodged against current renewable energy options, including environmental, transportation and land-use concerns, said Wes Bolsen, chief marketing officer and vice president of business development for Coskata.

In the three-step process, carbon-based materials are converted into synthesis gas using well-established gasification technologies. After the chemical bonds are broken using gasification, microorganisms licensed to Coskata as part of the OSU Biofuels research convert the resulting syngas into ethanol by consuming carbon monoxide and hydrogen in the gas stream. Once the gas-to-liquid conversion process has occurred, the resulting ethanol is recovered from the solution using vapor permeation technology.

The Coskata process has the potential to yield more than 100 gallons of ethanol per dry ton of carbonaceous feedstock, reducing production costs to less than $1 per gallon, Bolsen said.

According to an independent study conducted by the U.S. Department of Energys Argonne National Laboratory, Coskatas process using the OSU Biofuels Team microorganisms can reduce carbon dioxide emissions by as much as 84 percent compared to conventional gasoline.

The process also has no back-end solid waste to dry and handle like enzymatic approaches to ethanol production and uses les
'/>"/>

Contact: Donald Stotts
donald.stotts@okstate.edu
405-744-4079
Oklahoma State University
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. New partnership offers outsourced R&D in membrane biology
2. UD hosts conference on knowledge-based partnerships Nov. 2
3. Elsevier announces new journal partnership for 2008
4. Emory, Ohio State launch partnership in predictive and personalized health care
5. United Water, in partnership with Stevens, wins Management Innovation Award
6. MIT, Eni announce energy research partnership
7. New approach builds better proteins inside a computer
8. Obesity and the central nervous system -- the state of the art
9. University of Minnesota study refutes belief that black men have more aggressive prostate cancer
10. Iowa State University conference examines developing bioeconomy
11. University and state agencies to forecast local health effects of climate change

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/4/2009)...HILADELPHIA Although scientists are reluctant to ...n method, evidence continues to grow about its pro...published in Cancer Prevention Research , a journ..., which suggests some reduction in oral cancer. ,...f medicine in the Department of Thoracic/Head and ...
(Date:11/4/2009)...eavy traffic corridors in the cities of Long Beach...roportion of preventable childhood asthma, and the...n the disease has likely been underestimated, acco... California (USC). , The study, which appears i...blic Health , estimated that nine percent of all c...
(Date:11/4/2009)...ancouver, BC - Lowly bacteria, it turns out, hold ...turing plants around the world clean up toxic wast..., specifically RDX, were invented back in World Wa...decades. These high-energy compounds are often us...ful version of TNT. , But with increased knowl...
Breaking Biology News(10 mins):Does green tea prevent cancer? Evidence continues to brew, but questions remain 2USC study finds big air pollution impacts on local communities 2Genomic research will enable greener cleanup of military explosive test sites 2BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 1BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 2BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 3BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 4BioCryst Awarded Additional 2477 2 Million by the U S Department of Health 26 Human Services To Develop Peramivir for Influenza 57736 5DOR BioPharma Announces 249 4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 57734 1DOR BioPharma Announces 249 4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 57734 2DOR BioPharma Announces 249 4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 57734 3DOR BioPharma Announces 249 4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 57734 4DOR BioPharma Announces 249 4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 57734 5DOR BioPharma Announces 249 4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines 57734 6AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS 112 in Cancer 14165 1AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS 112 in Cancer 14165 2AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS 112 in Cancer 14165 3
...ug development : only "lucrative","markets" get ex...ve,seen very promising drugs candidates or related...de with it, even if millions would have,been saved...is to find,a drug candidate that affect a "profita...ne. PLoS Medecine has an article about a possible,...
...f the Chinese hybrid rice genome, which was publis...s have recently finished the fine map of the rice ...e of PLoS Biology (Vol.3 Issue 2, 2005), scientist...eported a "much improved, near-complete genome ana...sativa." , The fine maps of the rice genome seque...
...lar signaling mechanism whose existence has been,k...since the,identification of a mutant strain of Dro...Hunt Morgan’s lab in 1910. Later studies,revealed ...t extends,through both sides of the cell membrane ...partner, such as the protein Delta, presented,on t...
Other Biology News:Finding Cures For Tropical Diseases: Is Open Source An Answer? 2Whole genome fine map of rice completed 2Bound for destruction: Ubiquitination protects against improper Notch signaling 2Bound for destruction: Ubiquitination protects against improper Notch signaling 3
(Date:11/6/2009)...OOK, N.Y., Nov. 6 BioSpe...harmaceutical company developing first-in-class co...ncial results for the third quarter ended Septembe...in September of this year, the FDA,s Arthritis Adv... of 12-0, the approval of XIAFLEX(TM) for the trea...
(Date:11/6/2009)...IENNA, Austria, November 6 EUCODIS...nufacturing, and marketing enzymes for the,chemica...o a research,agreement with Bio Sidus, the leading..., The agreement gives EUCODIS Bioscience exclu...t - to Bio Sidus, proprietary collection of,psychr...
(Date:11/6/2009)...RY, Nov. 6 /PRNewswire-FirstCall/ - Oncolytics Bio...the "Company") today announced updated results fro...atients with sarcomas metastatic to the lung in a ...Tissue Oncology Society Meeting held in Miami Beac...resentation, entitled "A Phase II Study of Intrave...
(Date:11/5/2009)...ORTATION -- Gone hybrid . . . , Fuel economy r... now posted at the www.fueleconomy.gov web site,... maintains for the U.S. Department of Energy and t...he top 10 vehicles on the best fuel economy list a...PG city; 48 highway). "This list proves that hybri...
Breaking Biology Technology:Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 6EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 2November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 3
...ent Response to Novel Beta Blocker ...dolol, an investigational,pharmacologically unique...reduces hospitalization and death among heart fail...ing to results of a large DNA study presented,toda...ailure Society of,America. Researchers found that ...
...US$10 million received based on the positive revie...ultiple sclerosis trial - EDMONTON, Sept. 22 /PRN..., a leading developer in the treatment of multiple...ved the US$10 million milestone payment from its,p...ment is based on the previously announced positive...
...l Systems and BrainLAB enabling, non-invasive tr...vous system, PALO...ctors around the globe are turning more and,more t... for the treatment,of cancer and other conditions.... Systems (NYSE: VAR ) and BrainLAB, doctors are p...
Other Biology Technology:Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes 2Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes 3BioMS Medical announces receipt of milestone payment from Eli Lilly and Company 2Non-Invasive Radiosurgery with Novalis Tx(TM) Platform Rolling Out Worldwide 2Non-Invasive Radiosurgery with Novalis Tx(TM) Platform Rolling Out Worldwide 3Non-Invasive Radiosurgery with Novalis Tx(TM) Platform Rolling Out Worldwide 4Non-Invasive Radiosurgery with Novalis Tx(TM) Platform Rolling Out Worldwide 5
Anti-Endomorphin-2 Polyclonal Antibody, Unconjugated from CHEMICON
...0kb), and large plasmid insert (10-20kb) DNAs. Gre... command 20-50 fold copy amplification for high yi...ble with blue-white screening (pEZ BAC) or transcr...sert stability. Kits include electrocompetent cell...
PCRX Enhancer System from Invitrogen
Goat Anti-MAGP-2 (C-19) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
Biology Products: